While commonly known for degradation of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential for use in targeting of bioactive and imaging agents in cancer treatment. MMPs are upregulated at all stages of expression in cancers. A comprehensive analysis of published literature on expression of all MMP subtypes at the genetic, protein, and activity levels in normal and diseased tissues indicate targeting applicability in a variety of cancers. This expression significantly increases at advanced cancer stages, providing an improved opportunity for controlled release in higher-stage patients. Since MMPs are integral at every stage of metastasis, MMP roles in cancer are discussed with a focus on MMP distribution and mobility within cells and tumors for cancer targeting applications. Several strategies for MMP utilization in targeting -such as matrix degradation, MMP cleavage, MMP binding, and MMP-induced environmental changes -are addressed.
Introduction
Adverse effects prevalently accompany cancer chemotherapy. To reduce these adverse effects and improve patient quality of life, it is imperative that advancements to current treatments be made. Development of novel systems to target, localize, and prolong residence time of bioactive compounds within cancerous tissues has the potential to minimize deleterious off-target effects in healthy tissue. To achieve enhanced exposure of cancer tissue to drug, drug delivery systems (DDSs) can be designed to respond to the tumor and metastatic microenvironments for localized action. The cancer microenvironment often differs from healthy tissue via extracellular matrix (ECM)-degradation protein concentrations [1] . As a subclass of ECM-degradation proteins with large concentration differences between healthy and cancer tissues, matrix-metalloproteinases (MMPs) yield themselves as opportune candidates for localized delivery.
What are MMPs?
MMPs are calcium-dependent endopeptidases that utilize three amino acids as ligands for zinc ion coordination to achieve their catalytic action. To date, 23 MMPs have been discovered in humans (MMP-23A and MMP-23B are considered as one protein in this review, as they are identical proteins encoded by a duplicated gene [2] ). The various MMPs each recognize and cleave specific peptide sequences commonly found in a variety of ECMs and other components [3] , with the most typical substrates being many collagen types [4] [5] [6] , gelatin [7] , aggrecan [8] , laminin [9] , elastin [6, 10] , fibronectin [11, 12] , fibrinogen [13] , and fibrin [14] . Substrate specificities and amino acid sequences have led to classification of MMPs into various categories, i.e., the collagenases (MMP-1, MMP-8, MMP-13), the gelatinases (MMP-2, MMP-9), the stromelysins (MMP-3, MMP-10, MMP-11), the matrilysins (MMP-7, MMP-26), and membrane-type (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 MMP-25) [15] . Seven other MMPs are not classified into substratedependent groups, with many of their corresponding substrates dependent upon the tissue or cells in which these MMP subtypes are mainly expressed (MMP-12: macrophages [16] ; MMP-19: placenta, lung, pancreas, ovary, spleen, intestine [17] ; MMP-20: enamel [18] ; MMP-21: ubiquitous within tissues [19] ; MMP-23: reproductive tissues [20] ; MMP-27: ubiquitous in all tissues except brain [19] ; and MMP-28: testis, keratinocytes [21] ) [22] . The specific substrates of the various MMPs are summarized in the reviews by Visse and Nagase [22, 23] .
All MMPs are synthesized in an inactive proenzyme state in which the zinc-containing catalytic domain interacts with a cysteine residue [24, 25] . Disruption of this zinc-cysteine interaction via activation factors partially activates the enzyme and promotes the autocatalysis of the propeptide region, rendering the MMP fully active [26, 27] . Membrane-type MMPs and the secreted furin-activated MMPs (MMP-11, MMP-21, MMP-28) are known to undergo activation intracellularly, followed by either immediate lipid membrane localization or extracellular secretion, respectively [23, [28] [29] [30] [31] [32] [33] [34] . Other secreted MMPs are activated extracellularly via various mechanisms [35] [36] [37] . MMP-2 is commonly activated from its proenzyme state at the cell surface by forming a complex with an activated membrane-associated MMP [38] . In the laboratory, mercurial compounds can be utilized to induce activation [39] . MMP activation is a highly regulated step, dependent on MMP type, but generally influenced by soluble factors, ECM-cell interactions, and cell-cell interactions [40] . Inhibitors, such as tissue inhibitors of metalloproteases (TIMPs), serve to reduce activity of activated MMPs; however, latent gelatinases can form complexes with TIMPs to promote MMP-2 activation or for other unknown functions [41, 42] .
MMPs are generally either excreted into the extracellular environment or remain membrane-bound; however intracellular MMP concentrations are often present. When in the intracellular environment, most MMPs remain preserved in a latent proenzyme state [43] , yet activated forms and even novel isoforms have been identified intracellularly [28, 44, 45 ].
Biological function of MMPs
Classically, MMPs are known as ECM degradation enzymes, ultimately having effects on ECM dynamics and fundamental cell behaviorproliferation [46] , adhesion [47] , migration [48] , differentiation [49] , and apoptosis [50] . While each subtype targets specific substrates, MMPs recognize and cleave specific peptide sequences of the various ECM protein components. The three-dimensional structure of ECM components affects the cleavage capability of individual MMP subtypes [51] , despite MMP catalytic domain polypeptide folding being only slightly altered among subtypes [16] . The important roles of MMPs in ECM remodeling provide broad potential impacts in the immediate external cellular environment.
However, MMP biological function is not limited to the ECM. Interestingly, approximately only 20% of MMP substrates are ECM molecules and regulators [52] . Other MMP substrates include receptors [53] , growth factor binding proteins [54] , and cytokines [55] . In fact, neither MMP-11 nor MMP-23 have any known ECM substrates, exhibiting only very weak ECM activity [22, 23, 56, 57] . This pleiotropy leads to a myriad of effects in enzyme activation [58] , cell signaling regulation [59] , chemokine processing [60] , and membrane shedding [61] , with ultimately larger-scale impacts in embryogenesis and embryo development [62] , tissue morphogenesis [63] , tissue homeostasis [64] , wound healing [65] , and inflammation [53] . As expected with the wide range of effects, MMP dyshomeostasis has been associated with several diseases, including arthritis [66] , cardiovascular diseases [67] , pulmonary diseases [68] , and cancer [69] . The biological function of MMPs is addressed more extensively in external reviews by Vu, Löffek, and Rodríguez [70] [71] [72] .
Targeting of MMPs
As degradation enzymes with promiscuous substrate specificity, MMPs provide an avenue for localized controlled release of anticancer drugs at or near tumor tissues. To highlight the potential advantages of MMPs as cancer targets, this review will address MMP upregulation and overexpression in cancer, role in metastatic disease, and distribution and motility in and around cancer environments. Furthermore, a brief evaluation of current utilization of MMPs as targets will be discussed. In summary, this mini-review will focus on the use of MMPs as targets for localization and controlled release of bioactive agents in the treatment of cancer. Design and development of drugs for MMP inhibition has been thoroughly discussed in other reviews [15, [73] [74] [75] .
2. Matrix metalloproteinases in cancer: why are they worthwhile targets?
Regulation and expression
MMPs are regulated at many levels [76] : (1) RNA transcription, (2) protein synthesis, (3) secretion and intracellular trafficking, (4) subcellular or extracellular localization (compartmentalization), (5) zymogen activation, (6) endogenous protease inhibitor expression levels, and (7) MMP degradation (inactivation). Upregulation of at least one MMP subtype has been observed for all of these regulatory stages in at least one form of cancer [77] [78] [79] [80] [81] [82] [83] .
To comprehensively evaluate MMP upregulation in cancerous tissues, a database categorizing 70 peer-reviewed journal articles was created for this review, in which the genetic, protein, and activity levels were distinguished. Of the articles included in the database, methods utilized for upregulation quantification included: immunohistochemistry, qPCR, microarray analysis, Western blotting, ELISA, substrate zymography, and fluorogenic MMP substrates. Despite having discovered MMP upregulation in a variety of fluids (pleural effusion fluid [84] , serum [85] , plasma [86] , ascitic fluid [87] , sputum [88] , pancreatic juices [89] , urine [90] , fecal material [91] , bronchoalveolar lavage fluid [92] , nipple aspirate fluids [93] , and cerebrospinal fluid [94] ), only literature evaluating normal and diseased human tissues was included in the database. Serum and plasma MMP concentrations were not included as upregulated cancer patient serum concentrations are often an order of magnitude lower than tissues obtained from healthy patients [85, 95] . The analysis weighted studies by number of patients in order to reduce the impact of outlier tissue samples. Complete database methods (including limitations to the analysis) are available in supplemental information (Methods S1). Database results showing upregulation levels in many forms of cancer for the most studied MMPs (MMP-1 through MMP-9) are shown in Table 1 , and less-studied MMPs (MMP-10 through MMP-28) are included in Table S1 . In Table 1 and Table S1 , healthy and cancer tissue expression refers to the percentage of tissue samples deemed to have sufficient MMP subtype expression by immunohistochemistry to be considered positive for the expression of the MMP by the authors of the individual studies.
While whether all or only specific MMP subtypes exhibit upregulation remains disputed, several MMPs show N 10-fold average genetic, protein, and/or activity expression increases (Table 1) . Furthermore, the level of upregulation positively correlates with cancer stage, as illustrated in Fig. 1 (data obtained from the compiled database), which represents an analysis comparing the patient tissue immunohistochemical expression, genetic expression, protein expression, and activity levels of all MMP subtypes in all cancer types against patient population cancer stage (see Methods S2 for complete methods and limitations of analysis). While only the genetic and protein expression correlated to statistical significance (p = 0.007, p = 0.017, respectively), expression levels in all evaluated cases were shown to positively correlate with increasing cancer stages. The consequences of MMP upregulation are grave, as increased MMP subtype expression has been correlated with increased angiogenesis [96] , cell proliferation [46] , and cell migration [97] , and shown to decrease cancer cell sensitivity to natural killer cells [98] . MMP upregulation is further associated with increased regional lymph node [99] and brain metastases [100] , higher TNM stage [101] , poorer patient survival [102] , greater tumor invasion depth [103] , poorer tumor differentiation [104] , greater likelihood of recurrence [105] , and poorer prognosis [106] . However, as their concentrations are increased in both primary and metastatic tumors, MMPs make strong candidates as targets for [243] [244] [245] [246] [247] 284] systemic delivery for controlled release of chemotherapeutics, unlike many biomarkers that show significant differences in expression between primary and metastatic tumors [107] [108] [109] [110] . Furthermore, the lower MMP expression within the bloodstream compared to both healthy and tumor tissues can reduce intra-vessel drug release from properly-engineered systemic delivery vehicles during transport [further discussed below in MMP-cleavage from nanocarriers].
Role in metastasis
Metastasis is the predominant cause of mortality for most solid tumor cancer [111] , and MMPs play a multi-layered and pivotal role in metastasis [111, 112] . Evidence supports both pro-metastatic and antimetastatic roles of MMPs [113] , yet MMPs are known to be involved in every stage of metastasis formation [113] [114] [115] . MMP-7 converts Ecadherin, a cell-cell adhesion protein, into a soluble form in cancer, allowing cancer cells to dislodge from the bulk tumor and become motile [116] . As MMPs degrade the surrounding ECM components (including the basement membrane), a migratory pathway is created through which local invasion of tumor cells is facilitated [117] [118] [119] . Cleavage of fibrous ECM proteins exposes normally hidden sites and epitopes which can have biological activity that promote growth [119] . Increased MMP activity also alters the structural tension in the matrix, altering mechanotransductive forces and leading to changes in cell-matrix signaling cues [120] . The release of ECM-bound signaling molecules that are normally only exposed to the cell surface in a tightly-regulated manner often accompanies increased MMP activity and ECM fragmentation, which can further promote proliferation and mobility [121] . MMP activity also instigates cytokine and growth factor expression, conducive to angiogenesis, tumor growth, and metastasis [113] . MMP roles in metastasis are not confined to only the localized ECM. Tumor cell intravasation into the circulation has been shown to be supported via MMP-1 regulation of endothelial permeability and transendothelial migration [122] . Furthermore, MMPs are directly involved in capillary wall adhesion after circulatory transport due to removal of endothelial cell adhesion molecules and formation of invadopodia, potentially playing a role in localization of metastases [114, 115, [123] [124] [125] . After metastatic cell entrance into tissues, membrane-associated MMPs facilitate adhesion to the regional ECM via CD44-shedding [126] . MMP-facilitated proteolysis of the ECM then allows for metastatic cell motility and settling into the new tissue, to begin the formation of a secondary tumor [127] . As MMPs are involved in the core metastatic functions of cancer cells, drug delivery mechanisms that target MMPs can essentially target cancer cells during all stages of metastasis.
Cellular distribution and mobility
While it may seem that membrane-bound and secreted MMPs have designated distribution, large MMP localization changes occur within cancer cells. Most intracellular MMPs reside in a zymogen state, yet besides proMMP-26, few MMP proenzymes are stored within the cells, as they are compartmentalized for membrane association or rapid secretion [128] . Interestingly, MMP-2 shows intracellular activity in nearly all healthy tissues [129] , but is often associated with apoptosis in healthy tissues [130] . Tumor cells show even higher intracellular gelatinolytic activity (likely from MMP-2) particularly at the invasive tumor front, yet apoptosis is not induced [131] . Like MMP-2, MMP-3 shows intracellular activity being highly associated with apoptosis, except in cancer [132] [133] [134] . MMP-1, MMP-7, MMP-8, and MMP-9 are also rarely activated intracellularly in healthy cells during times of cellular stress [135] , but reliable cancer-related intracellular activity studies regarding these MMPs are scarce. Evidence for intracellular activity has also been found for MMP-11, MMP-27, and the four Type-1 membrane-type MMPs via a normal furin activation mechanism, but these active MMPs seem to be rapidly transported to the membrane [33, 136] . One very interesting finding is that MMP-9 is known to permanently associate within the membrane of cancer cells -but not healthy cells -via unknown mechanisms [137] , yet only stromalassociated, not membrane-anchored, MMP-9 have been shown to affect growth and angiogenesis [138] . MMP mobility and compartmentalization within cells is known to be affected by interactions with many intracellular components (reviewed by Mannello [139] ), including through complex formation with natural inhibitors (MMP-9) [140] .
Tumor distribution and mobility
While MMP distribution throughout the tumor varies among cancer types, a few general trends can be claimed. MMP-2 shows greatest abundance at the invasive front, while the highest expression of MMP-7 and MMP-14 is found in the tumor center [141, 142] . MMP-9 is most abundantly found at the periphery in primary tumors, but within the tumor core in metastases [143, 144] . The invasive front shows the highest expression of MMP-11 [142, 145] . The most prevalent tumor distribution of commonly studied active MMPs is illustratively represented in Fig. 2 , using data from the following studies [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] . Tumors exhibit the greatest metastatic activity when MMP expression is highest in all regions of the tumor (when MMP/TIMP ratio is highest in both tumor center and invasive front) [142] . MMPs, in general, can be found with high expression in many tumor surrounding cells, such as ECM cells, immune cells, fibroblasts, and endothelial cells [155] . This broad expression provides plenty of opportunities to use MMPtargeting techniques for the localization of therapeutic compounds within the immediate cancer cell vicinity. Due to the large variation in MMP subtype distributions, special consideration must be taken in electing a particular subtype as a drug delivery target. Nevertheless, one cannot ignore that secreted MMPs are highly mobile, showing substantial diffusion even within the ECM environment that can cause changes in subtype tumor localization [156] .
Strategies for targeting
MMP-based targeting strategies are rapidly diversifying (Fig. 3) . While many drug delivery systems rely on delivery of already active drugs, MMP-targeted systems often deliver MMP-activatable prodrugs, covered in external reviews [157, 158] . 
Matrix degradation
The enzymatic activity of MMPs can be leveraged to create release depots that dynamically respond to their environment [159] . Hydrogels are comprised of soluble polymers cross-linked together via chemical or hydrogen bonds, electrostatic attraction, or van der Waals interactions. By incorporating sequences in the polymeric network -most frequently peptides -that are cleavable by MMPs, cleavage of polymer backbones, side chains, and/or crosslinks can be designed to occur within tumor microenvironments. This cleavage results in swelling and eventual degradation of the gel, which can be utilized to accelerate the release of bioactive molecules from the matrix [160] . These strategies have been extensively explored within the field of tissue engineering, but to a far lesser extent in drug delivery. Two strategies exist for implantation of macroscale matrices into cancerous tissue: first, surgical implantation either through direct placement or depositing the material in the void following tumor resection; second, injection of an in situ gelling solution from a needle or catheter.
MMP-responsive silk-elastinlike protein polymers (SELPs) have been investigated for the delivery of adenoviruses to head and neck squamous cell carcinoma and other bioactive compounds from an in situ gelling matrix [161] [162] [163] [164] . SELPs are constructed using recombinant genetic techniques to combine the strength of silk and the biocompatibility and thermoresponsive solubility of elastin with exquisite control over sequence, silk:elastin ratio, and molecular weight [165] [166] [167] . An injectable in situ gelling SELP polymer construct, SELP 815K (which contains 6 repeats of 8 silklike GAGAGS units, 15 elastinlike GVGVP units, and one lysine-substituted elastinlike GKGVP unit), with MMPresponsive sequence inserted into the elastin block, at the boundary between silk and elastin blocks, and within the silk blocks, undergoes a thermal liquid-to-solid transition between room and body temperature [160, 168] . Location of the MMP-responsive sequence affected gel mechanical properties, the degree of responsiveness, and survival outcome in animals [161, [168] [169] [170] . When the MMP-responsive sequences are incorporated into the elastin backbone or flanking regions, mechanical properties are preserved; however, insertion of the sequences into the silklike units, responsible for crosslinking within SELP gels, drastically decreased the mechanical rigidity and accelerated release of virus and degradation in vivo. MMP-directed release of viral gene therapy from MMP-responsive SELP hydrogels was shown to improve survival over non-responsive SELP gels and intratumoral injection of virus [170] .
Implantable hydrogel-based devices have been created to selectively deliver therapies that respond to the degree of MMP activity in the local environment. These hydrogels are designed to be inserted into the postresection cavity of glioblastoma multiforme (GBM) patients to prevent relapse from residual cancer cells [159] . Poly(ethylene glycol) (PEG)-based hydrogels were created with cisplatin attached pendantly via MMP-2 cleavable peptides (GPLGVRC) and shown to only release therapeutics in the presence of MMP-2 [171] [172] [173] [174] . The rate of degradation was primarily influenced by the ability of MMPs to penetrate into the matrix and enzymatic kinetics, rather than drug diffusivity [174] . Several other polymers could be potentially utilized in the future development of these systems.
In designing MMP-responsive matrices, one must consider base therapeutic release levels, polymer concentration, number of MMPdegradable sequences per polymer, and location of MMP-responsive sequences within the gel structure. A key design parameter to consider for this type of construct is the correlation between polymer density, porosity, and release, as release rates will not be dependent upon MMP activity for readily diffusible therapeutics. One method to overcome this obstacle is the tethering of freely-diffusing compounds to the matrix with degradable linkers in many particle-based systems [see MMP-cleavage from nanocarriers]. Pore size must be sufficient to allow MMPs access to cleavage sites. The polymer concentration within the gels will also impact release profiles, with lower polymer concentration increasing responsiveness of the constructs to MMPinduced release [170] .
MMP-cleavage from nanocarriers
Anticancer drugs may be attached to nanocarriers via MMPcleavable linkers. These peptide linker sequences can be tailored for particular MMP subtypes and have been shown to significantly enhance drug release when compared to a scrambled peptide linker [175] . Several different MMP-sensitive nanocarriers have been developed, including natural polymer-drug conjugates [176, 177] , synthetic polymer-drug conjugates [178] , micelles [179] , liposomes incorporating tailored lipopeptides [180] , nanovesicles [181] , and self-assembling peptide fragments [182] . These systems have been used for delivery of chemotherapeutics [183] , prodrugs [184] , and siRNA for gene therapy [185] . Many anticancer drugs have been developed using solely MMPcleavable linkers for activation of prodrugs, viruses for gene therapy [186] , or toxins [187, 188] without the use of a nanocarrier. Recently, alterations have been made that combine matrix degradation with systemic delivery by incorporating the cleavage sites directly within the nanocarrier main structure, instead of linkers between pendant groups [189] [190] [191] . These novel approaches increase tumor penetration depth of the free drug due to the shrinking of the particle conditional upon degradation, as evidenced by a dendrimer-based gelatin matrix nanoparticle DDS [192] .
Theranostic approaches are now being developed, as shown by Ansari et al. with a MMP-14-cleavable linker to activate a prodrug while simultaneously initiating fluorescence. However, it must be noted that the utilized cell line abnormally overexpressed MMP-14 (over 1000-fold) when compared to other cancer cell lines [193] . Level of targeted MMP overexpression was determined to be highly significant for therapeutic efficacy of MMP-cleavable nanocarriers in a separate study that compared in vivo efficacy against cancer cell lines with differing MMP expression for tumor models [178] . Unfortunately, the majority of these systems have only been evaluated against primary tumors, and very limited studies regarding metastatic localization and release are available. One recent study utilizing a MMP-cleavable linker to a photosensitizer for photodynamic therapy provides promising evidence in destruction of bone metastases in vivo [194] .
As active MMPs are known to circulate in the bloodstream [195] , MMP-cleavable nanocarriers risk premature systemic release of free drug. However, MMP concentrations within the bloodstream of cancer patients have been shown to be approximately 10-fold or more lower than even the healthy tissues of those same cancer patients [85, 95] , indicating that bloodstream MMP activity should be a concern for offtarget drug release dependent upon circulation time. Moreover, ideal nanocarriers would be designed to release their drug cargo above a certain MMP concentration threshold in order to reduce systemic free drug concentrations and minimize release within healthy tissues. A concentration threshold-dependent release of drug from nanocarriers could allow for sufficient time for clearance from healthy tissues and decrease side effects.
MMP-targeting via ligand binding
Increased expression of MMPs in solid tumors and metastases makes them attractive for targeting by binding antibodies or peptides [69] . In traditional ligand-based targeting, a binding element is attached to a therapeutic carrier. When the binding ligand contacts its target, the carrier is trapped and elevates the local therapeutic concentration. Once such targeting peptide is cyclic peptide inhibitor (CTT), CTTHWGFTLC, which binds specifically as an inhibitor to the gelatinases, MMP-2 and MMP-9. CTT has been used to enhance the delivery of liposomes and protein nanocages compared to non-targeted vessels in vivo in murine cancer models [196] [197] [198] [199] . Given the peptidic nature of CTT, it can also be seamlessly grafted onto biologics to enhance their accumulation in rapidly growing tumors [200] . As part of a triple fusion protein, CTT was combined with endostatin mimic and kringle 5 (AARP), which are recombinant versions of endogenous antiangiogenic agents. Testing in a syngeneic mouse model with Lewis lung cancer cell line (LL/2) showed that the fusion peptide with CTT was more effective at retarding tumor growth than clinical endostatin. In vitro and histological testing showed AARP more effective in suppressing endothelial cell activation (proliferation, migration, and tube activation) [201] . MMP-targeting peptides can be used to enhance localization into tumors and increase the efficacy of therapeutic cargo. A key challenge for MMP targeting is the existence of many counter-targets, proteins that are homologous to the target but have no significant role in the disease, and antitargets, proteins with essential functions whose down-modulation results in clinically unacceptable side effects [2] .
MMP-binding peptides and anti-MMP antibodies have been investigated for the purpose of drug delivery to only a very limited extent [159, 202] ; however, targeting individual MMP subtypes could potentially lead to drug localization at particular sites along the cancer cell membrane or within a broader tumor region. Several peptides utilized by MMP inhibitors bind to many MMP subtypes [203, 204] , yet the majority of these inhibitors have shown mediocre efficacy in clinical trials [73] . While MMP subtype-specific inhibitors are now recommended for MMP inhibition [205] , use of broad-spectrum MMP-specific peptide sequences in MMP-binding drug delivery systems could potentially bypass limitations of specific MMP subtype targeting [206] . Furthermore, an entire MMP inhibitor (not just a peptide) was investigated as a MMP-imaging theranostic when radiolabeled TIMP-2 was designed for Kaposi sarcoma [207] . In a study of five human patients, however, the tracer was shown to predominantly distribute to the kidneys with no distinguishable signal in other tissues, casting doubt on TIMP effectiveness for localization of drugs to tumors [208] . Several labs have combined targeting elements for other targets, such as CD44 [209] or HER2 [210] , with MMP-cleavable linkers that function as secondary selection factor to trigger drug release or activate cell penetrating peptides after tumor accumulation [199, 211, 212] . However, as these particles used MMP-cleavable linkers rather than binding peptides, they are considered to use MMP-cleavage as their mode of targeting for the purpose of this review [see MMP-cleavage from nanocarriers].
Targeting MMP-induced environmental effects
The increased MMP activity leads to an altered tumor microenvironment, which in itself can provide opportunities for targeting strategies. Some of these changes include increased degradation of proteins and ECM components, such as collagen, laminin, and proteoglycans. A few examples of potential tumor microenvironment targets altered by MMP upregulation include increased fibronectin levels [213] , amplified concentrations of lysyl oxidase (LOX) [214] , the increased expression of MMP inhibitors [215] , the denaturation of collagen in localized cancer ECMs [216] , and greater CD44 cleavage. A fibronectin-targeting peptide attached to an MRI contrast agent effectively detected micrometastases and could easily be utilized for therapeutic delivery [217] . A peptide sequence with favorable kinetic properties for LOX-mediated peptidyl lysine oxidation has also been utilized for targeting of LOX environments [218] . While the majority of targeting of TIMPs has been directed toward gene regulation for MMP inhibition, TIMPs are non-intuitively upregulated alongside MMPs in cancers, likely due to their complexation with gelatinases having MMP activation functionality and their cell proliferation stimulation. Anti-TIMP-1 monoclonal antibodies have been shown to effectively localize in neoplastic tissues and provide an opportunity for drug targeting [219] . Collagen-mimetic peptides (CMPs) are shown to preferentially bind to denatured collagen via a triple helical peptide assembly and provide one of the most intriguing avenues for targeting MMP-induced effects in cancer drug delivery [220, 221] (see Fig. 3 ). Cleaved CD44 is known to be targeted by hyaluronic acid and has been investigated for drug delivery applications with promising results in the circumvention of chemoresistance [222] . One could contest that these mechanisms are essentially targeting other ECM components besides MMPs, yet we felt that MMP-induced environmental effects merited consideration as a targeting method to allow comprehensive evaluation.
Enhancing MMP upregulation
MMPs are upregulated via a variety of mechanisms, several of which involve external stimuli. While external triggering of local overexpression of MMPs to enhance efficacy of drug delivery has scarcely been investigated, this approach merits discussion in MMP-responsive cancer drug delivery. External upregulation of MMPs could likely advance cancer progression; however, the added efficacy of a highly potent compound released in concentrated MMP environments could be worth pursuing. Higher levels of targeted MMP expression when tested with MMP-responsive nanocarriers have been correlated with quicker degradation and release kinetics [160] , increased dose administration [178] , and reduced tumor volume [178] . With further investigation, one may find an enhancement of localization, lessening of off-target side effects, and improvements in overall survival.
Mild hyperthermia (39°C for 240 min) has been shown to upregulate MMP-2 and MMP-9 protein concentrations by 147% and 78%, respectively [223] , likely caused by heat shock protein upregulation [37] . Further methods to externally increase MMP activity include mechanical induction to replicate a more rigid ECM [224] , injection of MMP regulators [225] , gene delivery [226] , or oxidative stress [227] . Curiously, mechanical induction of MMP overexpression in MDA-MB-231 cells was correlated with advanced resistance to free drug chemotherapeutics, but was not tested against MMP-induced controlled release systems [224] . This enhanced chemoresistance has been observed in various other studies evaluating high expression of MMPs (not externally induced) as well [228] [229] [230] [231] [232] . Clearly, enhancing efficacy of MMPresponsive drug carriers via external MMP upregulation merits further investigation.
Conclusion and future directions
Overexpression and corporeal distribution in cancers qualify MMPs as a target for use in engineering drug delivery systems for controlled release. Due to the strong variability among MMP subtypes, further analysis is needed to define specific subtype expression profiles with individual cancers. Initial MMP-sensitive drug delivery systems have yielded substantial promise in improving localized pharmacological effect while limiting off-target effects in cancer. While a comprehensive evaluation of the efficacy of MMP-sensitive drug delivery systems on metastases has yet to be performed, novel methods utilizing MMP proteolytic activity for cancer-responsive drug delivery are likely to be developed. Externally enhancing MMP expression in localized regions could prove beneficial in supplementing MMP-targeted systems achieve much-needed efficacy. 
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